May 6th 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Promising Combinations Surpass Standard of Care in Advanced Renal Cell Carcinoma
October 9th 2019In an interview with <em>Targeted Oncology </em>at the<em> </em>2019<em> </em>Kidney Cancer Research Summit, McGregor, discussed emerging combinations and novel agents for the treatment of RCC.
Read More
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 7th 2019Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Watch
ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer
October 4th 2019The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
Read More
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Addition of Telaglenastat to Everolimus Extends PFS in Metastatic RCC
September 28th 2019Glutaminase inhibitor telaglenastat added to everolimus extends progression-free survival in patients with heavily pretreated advanced renal cell carcinoma compared with everolimus monotherapy, according to data from the phase II ENTRATA study presented at the 2019 ESMO Congress.
Read More
Annual Hematology Meeting Cochair Encourages Embracing of CAR T-Cell Therapy
September 24th 2019Now in it 24th year, the annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma, hosted by Physicians’ Education Resource, LLC, continues to bring significant advances in hematology to the forefront.
Read More
Expert Suggests Novel Approaches To Improve CAR Therapies in ALL
September 13th 2019To improve the efficacy of chimeric antigen receptor T-cell therapies, Nirali N. Shah, MD, MHSc, suggested including new constructs that target more than 1 antigen in patients with acute lymphoblastic leukemia, during a presentation at the 2019 SOHO Annual Meeting.<br />
Read More
Updated TIVO-3 Data Show OS Findings for Tivozanib in Highly Refractory Metastatic RCC
September 12th 2019A hazard ratio for overall survival of 0.99 for tivozanib versus sorafenib in patients with refractory metastatic renal cell carcinoma, according to findings from the second prespecified analysis of the TIVO-3 trial, AVEO Oncology announced.
Read More
Neelapu Discusses Toxicities Associated With CAR T Cells in Large B-Cell Lymphomas
August 29th 2019In an interview with Targeted Oncology, Sattva S. Neelapu, MD, discussed the evolving role for CAR T-cell therapy in patients with B-cell lymphomas. He also highlighted the toxicities commonly associated with these therapies and how physicians can treat these AEs as they arise.
Read More
CAR T-Cell Therapy Poised to Become Routine Care in CLL
August 13th 2019The initial pilot study of CTL019 in heavily pretreated CD19-positive hematologic malignancies demonstrated the feasibility of CAR T-cell therapy in patients with CLL. A presentation at the 2019 American Society of Gene & Cell Therapy Annual Meeting reported 2 cases of chemotherapy-resistant CLL, with ongoing follow- up at 8 years showing persistence of CAR-engineered T cells and sustained remission, as determined by flow cytometry and deep sequencing of immunoglobulin H rearrangements.
Read More
Four-Year Follow-Up Data Confirm Durable Responses With CAR T-Cell Therapy in B-Cell Lymphomas
August 7th 2019In an interview with <em>Targeted Oncology</em>, Chong, a fellow at the University of Pennsylvania, discussed the 4-year follow-up data for CAR T cells in patients with DLBCL and FL. She also addressed the challenges that need to be overcome in order to give more patients access to this type of therapy.
Read More
MRD Reported Undetectable After Liso-cel CAR T-cell Therapy in CLL
August 2nd 2019In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.
Read More
Assessing the Role CAR T-cell Therapy Plays in Mantle Cell Lymphoma Treatment in ZUMA-2 Trial
July 31st 2019Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with <em>Targeted Oncology</em>.
Read More
Survival Benefit With Nivolumab Still Seen at 5 Years in Melanoma, RCC, and NSCLC
July 31st 2019Nivolumab demonstrated long-term survival benefit in heavily pretreated patients with advanced melanoma, renal cell carcinoma, and non–small cell lung cancer, according to an analysis of 5-year results from the CA209-003 trial. The analysis also identified favorable and adverse factors associated with survival that could inform future use of nivolumab.
Read More